Westlake Village, CA- Apr.22, 2015 – Tarcine BioMed USA, Inc. today announced that Tarcine BioMed Inc. (Hong Kong) has officially signed a Memorandum of Understanding (MOU) with POC Medical Systems, Inc. (Livermore, CA). Tarcine BioMed is exploring collaboration with POC Medical Systems to form a Joint venture in China. This Joint venture will focus on advancing the early warning systems established by Tarcine onto the proprietary Pandora CDx Platform from POC Medical Systems for Myocardial Infarctions and cancers. Tarcine has been searching for a system that rapidly deploys its portfolio of early detection of cancer, myocardial infarction warning, and infectious disease diagnostic tools.
“Tarcine has long been searching for a game-changing innovative technology onto which we can port our existing product line to enhance value to our customers – we finally found it,” says Ray Jiao, CEO of Tarcine. Under the terms of the MOU Tarcine will pay development costs in exchange for an exclusive world-wide licensing option to sell the Pandora system for the field of testing blood samples for the following applications: Nasopharyngeal carcinoma, stomach cancer, pancreatic cancer, colon cancer, liver cancer, esophageal cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, testicular cancer, and myocardial infarctions. The MOU also outlines steps and a clear timeline for the formation of the joint venture.
Sanjeev Saxena CEO of POC Medical System adds, “This milestone for POC is a major step toward the establishment of our first joint venture into one of our largest markets in the world.”
About Tarcine BioMed, Inc.
Headquartered in Hong Kong, Tarcine is an innovative diagnostic company with global presence. Our core mission is to build a leading diagnostic company dedicated to Cancer and Myocardial Infarction warning in China. Tarcine is a fully integrated entity covering R&D, regulatory filing, manufacturing, and sales & marketing. One of Tarcine’s leading products in China is the first-in-class Rta kit for nasopharyngeal Carcinoma (NPC). It is the only CFDA approved product for diagnosis and clinical management of NPC and has been officially listed in National family planning committee catalog since 2013. Tarcine BioMed USA is the business development center dedicated to helping our global business partners commercialize their diagnostic products in China.
Tarcine BioMed USA, Inc. contact:
Dr. Liana Bates
Tarcine Biotechnic Diagnostics Ltd, Hong Kong contact:
Mr. Francis Wu
email@example.com (852) 3907 0070
About POC Medical Systems, Inc.
POC Medical Systems is a Livermore, CA diagnostics technology platform company. Its mission is to deliver point-of-care diagnostic medical devices to enable early detection of life threatening diseases to provide access to high quality, effective, and economic diagnostic solutions for low resource settings –improving the quality of health care and saving lives-while delivering significant value to partners and investors.
POC Medical Systems, Inc. contact: